HELIVAC

Overpowering helminth-mediated immune-modulation is a route towards vaccine development against these major animal pathogens

Coordinatore	QUEEN'S UNIVERSITY BELFAST    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	2˙486˙332 €
EC contributo	2˙486˙332 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-ADG_20120314
Funding Scheme	ERC-AG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-06-01   -   2018-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	QUEEN'S UNIVERSITY BELFAST  Organization address address: University Road city: BELFAST postcode: BT7 1NN contact info Titolo: Mr. Nome: Ronan Cognome: Crossey Email: send email Telefono: +44 28 9097 1165 Fax: +44 28 9097 5182	UK (BELFAST)	hostInstitution	2˙486˙332.80
2	QUEEN'S UNIVERSITY BELFAST  Organization address address: University Road city: BELFAST postcode: BT7 1NN contact info Titolo: Prof. Nome: John Pius Cognome: Dalton Email: send email Telefono: +44 2890975787 Fax: +44 2890975877	UK (BELFAST)	hostInstitution	2˙486˙332.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Helminth (worm) pathogens cause >55% of all animal diseases which result in enormous losses to the global agricultural economy. Since the use of chemical products to treat worms is not sustainable in the long term because of the continual emergence of drug-resistant parasites and consumer concerns about what they eat, control by vaccines is the most appropriate way forward. However, there are presently no vaccines for any animal or human helminth pathogen. We hypothesise that the ability of helminth parasites to suppress the protective arm of the immune response explains why we have been unsuccessful in developing efficacious vaccines against these pathogens. During helminth infection the function of innate immune cells, dendritic cells (DCs) and macrophages, is manipulated by the parasite to create a T helper (Th) cell 2-driven immune response that is beneficial to its survival, while simultaneously suppressing the immunoprotective Th1-driven response. This helminth-induced immune modulation is induced by the secretion of specific parasite immunomodulatory molecules. Focusing on the helminth that causes animal and human fascioliasis (liver fluke disease), we will ‘turn-the-table’ on this parasite by targeting its immunomodulatory mechanisms and develop vaccine formulations that induce potent protective Th1-inducing humoral and cellular immune responses. The project involves both innovative and discovery approaches in the search for novel helminth immunomodulatory molecules, and a translational element that will bring these findings into a useful veterinary medicine application for the end-users, farmers and consumers. The breakthrough of this project, therefore, will not only be the development of a vaccine against liver fluke disease, but also the opening of a new route towards the control of many other major helminth pathogens of both animals and humans.'